36 results
Thumbnail

D1.274 - Anaphylaxis Risks in Beekeeping: The Importance of Developing a Health Education Program

Thumbnail

D1.284 - Trends in Recurrent Anaphylaxis Triggered by Food, Drug, and Insect Allergies from 2015 to 2021: A Population-Based Retrospective Cohort Study Using the National Insurance Claims Database of Japan

Thumbnail

D1.275 - Wheat-free diet restore the normal intestinal microbiome structure in patients with wheat-dependent exercise-induced anaphylaxis

Thumbnail

D1.276 - Social #anaphylaxis: how social media reveals shifting trends in public health concerns

Thumbnail

D1.278 - Chlorhexidine allergy in perioperative anaphylaxis: undeclared and overlooked

Thumbnail

D1.279 - Vit v 5: A Chitinase Implicated in Grape-Induced Anaphylaxis

Thumbnail

D1.282 - Identification of Thaumatin-like protein (Ole E 13) as a potential allergen in green olives, a case report

Thumbnail

D1.283 - Idiopathic anaphylaxis in a child, Alpha-gal syndrome. Is it an entity in children?

Thumbnail

D1.285 - Analysis of systemic food reactions in patients sensitized to Bet v1 in Madrid (Spain)

Thumbnail

D1.286 - Nebulized inhaled epinephrine versus epinephrine autoinjector for the treatment of food-induced anaphylaxis in young children – a randomized controlled clinical trial

Thumbnail

D1.287 - Lipid profiling of Co-factor Induced Anaphylaxis: The Impact of Exercise and Aspirin on metabolism

Thumbnail

D1.289 - Severe allergy to albumin after cesarean section

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab